Kibotide: Zinc PGA for Joint Health Backed by Zinc & IL-6 Science
Normalize joint immunity with KIBOTIDE.
Targeted zinc support for joint comfort.
What makes KIBOTIDE so special
KIBOTIDE: A Patented Formulation
- Evidence-Based Zinc: Formulated at the clinical dose (8.5mg) proven to reduce IL-6 and support joint health.
- Patented Zinc Delivery (γ-PGA): Proven science for better zinc absorption and delivery to where it matters for maximum benefit.
- Enteric-coated: Ensure safe prolonged use.
Proven by Global Research
The Meta-Analysis (Zinc vs. IL-6)
A comprehensive 2021 study (British Journal of Nutrition) confirmed that zinc supplementation is a clinically proven way to significantly reduce systemic IL-6 levels, normalizing the body's inflammatory response.
The 61% Bone Protection Factor
Data published in BMC Musculoskeletal Disorders (2024) found that optimal zinc intake is associated with a 61% lower risk of bone density loss.
High zinc intake reduced joint swelling and disease activity
A double-blinded clinical trial in 1976 (The Lancet) involving patients with chronic refractory arthritis found that high dose zinc treatment led to reduced joint swelling, morning stiffness, walking time, and the patient's own impression of overall disease activity.
From Immune-Oncology Research to Joint Care
Developed by Xylonix
KIBOTIDE was developed by Xylonix, a biotech specializing in advanced immune-oncology research and development. We took the rigorous science used in cancer research and applied it to daily joint and bone health. Learn more at xylonix.io.
Made in Korea
Every KIBOTIDE batch is produced in a world-class, GMP-certified facility located in Korea to ensure the highest quality.
